



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 033. INDIA.
Tel : +91 40 23547532, Fax : +91 40 23548243

24th April, 2014

Corporate Relationship Department
The Bombay Stock Exchange Limited
Dalal Sreet, Fort
Mumbai 400 001

The Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclose herewith the Press Release for your information.

Thanking you

Yours faithfully
For NATCO Pharma Limited

A handwritten signature in black ink, appearing to read "M Adinarayana".

M Adinarayana
Company Secretary &
Vice President (Legal &Corp Affairs)



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 033. INDIA.
Tel : +91 40 23547532, Fax : +91 40 23548243

Press Release

NATCO Pharma pleased with Federal Circuit's decision on Oseltamivir

Hyderabad, India, April24, 2014

Natco Pharma Limited and Alvogen, who have partnered with respect to the first substantially complete Abbreviated New Drug Application (ANDA) filed with the U.S. Food and Drug Administration (FDA) for the generic version of Tamiflu® oral capsules (oseltamivir phosphate), are pleased with the Federal Circuit's decision of April 22nd in the case of Gilead Sciences, Inc. et al. v. Natco Pharma Limited et al, 2013-1418.

In it, Circuit Judges Chen and Prost agreed with Natco and Alvogen that the earlier expiring Orange Book listed patent qualifies as an obviousness-type double patenting reference for the later expiring Orange Book listed patent. The case has been remanded to the District court of New Jersey where Natco and Alvogen will continue to challenge the validity of U.S. Patent No. 5,763,483. Natco may have First to File approval status for the Abbreviated New Drug Application (ANDA), contingent upon successful litigation outcome.

TAMIFLU® (Roche's trade name for Oseltamivir Phosphate) had U.S. sales of approximately \$495 Million for twelve months ending September 2013, according to IMS Health.

Forwarded for favor of publication
For NATCO Pharma Limited

M Adinarayana

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)